Business Context and Reporting Period
This Form 8-K was filed by Jupiter Wellness, Inc., although the request metadata identifies BONK, Inc. The report concerns an underwritten follow-on offering and was dated July 26, 2021; it was signed on July 30, 2021. No operating-period financial statements are included.
Offering and Key Financial Information
- The company entered into an underwriting agreement dated July 22, 2021, with Aegis Capital Corp. as sole book-running manager.
- The offering initially comprised up to 11,066,258 newly issued common shares, 540,884 shares sold by existing stockholders, and up to 11,607,142 warrants.
- Underwriters exercised their 45-day over-allotment option for an additional 1,741,071 common shares and 1,741,071 warrants.
- After exercise of the over-allotment option, the disclosed maximum aggregate securities were 13,348,213 common shares and 13,348,213 warrants, including shares sold by selling stockholders.
- The underwriting discount was 7.0% of gross offering proceeds, plus a non-accountable expense fee equal to 1.25% of gross proceeds.
- The filing text does not provide a clear offering price, gross proceeds, net proceeds, warrant exercise price, or expected use of proceeds.
- The filing provides no revenue, profit, cash flow, margin, debt, liquidity, or other operating metrics.
Material Changes and Other Terms
- The material event was the completion of the follow-on offering and the underwriters’ exercise of the over-allotment option.
- The company and its directors and executive officers agreed to lock-up periods of one year and 120 days, respectively, subject to exceptions and underwriter consent.
- The underwriting agreement contains customary representations, closing conditions, termination provisions, indemnification obligations, and contribution rights.
- The offering may increase the company’s share count and create potential future dilution from warrant exercises; the filing does not quantify the resulting percentage dilution.
Guidance, Risks, and Unusual Items
No financial guidance or operating outlook is provided. Key matters for investors include the final offering price and net proceeds, dilution from newly issued shares and warrants, the terms and exercise price of the warrants, selling-stockholder participation, and the company’s intended use of proceeds.
Investor Verification Checklist
- Verify the final closing terms, offering price, gross proceeds, underwriting expenses, and net proceeds.
- Confirm the number of shares issued by the company versus shares sold by existing stockholders.
- Review the warrant exercise price, expiration, anti-dilution provisions, and potential dilution.
- Confirm the company’s use of offering proceeds and updated liquidity position.
- Review the filed underwriting agreement and the press release for any terms not reproduced in the filing text.
- Resolve the exhibit-number discrepancy in the provided text, which refers to the press release as both Exhibit 99.2 and Exhibit 99.1.